Probiotics in Chronic Kidney Disease: Harmonizing Gut Health for Kidney Benefit
Article Sidebar
Main Article Content
Abstract
Chronic Kidney Disease (CKD) poses a significant global health challenge, necessitating innovative strategies to complement conventional treatments. This article explores the intricate relationship between gut health and renal function, specifically investigating the potential role of probiotics in managing CKD. The article explains the gut-kidney axis, emphasizing how imbalances in gut bacteria (dysbiosis) can accelerate CKD progression. The review describes the fundamental mechanisms by which probiotics influence the gut microbiome and discusses their ability to potentially mitigate the effects of dysbiosis. We examine clinical trial data to demonstrate the effectiveness of probiotics in potentially improving kidney function, reducing inflammation, and enhancing overall health among CKD patients. Challenges such as the variability in probiotic strains and potential side effects are also addressed. Finally, the article discusses the integration of probiotics into traditional CKD management approaches for a comprehensive therapeutic strategy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Tuttle KR, Jones CR, Daratha KB, Koyama AK, Nicholas SB, Alicic RZ, et al. Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020. N Engl J Med 2022;387(15):1430–1. doi: 10.1056/NEJMc2207018.
Kampmann JD, Heaf JG, Mogensen CB, Mickley H, Wolff DL, Brandt F. Prevalence and incidence of chronic kidney disease stage 3-5 - results from KidDiCo. BMC Nephrol 2023;24(1):17. doi: 10.1186/s12882-023-03056-x.
Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 2014;18(19):2918–26.
Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022;102(5):990–9. doi: 10.1016/j.kint.2022.06.013.
Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014;85(1):49–61. doi: 10.1038/ki.2013.444.
Cao C, Zhu H, Yao Y, Zeng R. Gut Dysbiosis and Kidney Diseases. Front Med (Lausanne) 2022;9:829349. doi: 10.3389/fmed.2022.829349.
Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol 2018;14(7):442–56. doi: 10.1038/s41581-018-0018-2.
Feng Z, Wang T, Dong S, Jiang H, Zhang J, Raza HK, et al. Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature. J Int Med Res 2021;49(10):3000605211053276. doi: 10.1177/03000605211053276.
Fagundes RAB, Soder TF, Grokoski KC, Benetti F, Mendes RH. Probiotics in the treatment of chronic kidney disease: a systematic review. J Bras Nefrol 2018;40(3):278–86. doi: 10.1590/2175-8239-jbn-3931.
Campos LF. Probiotics in CKD: waiting for the evidence. J Bras Nefrol 2023;45(2):136–7. doi: 10.1590/2175-8239-JBN-2023-E005en.
Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Goma-Garces E, Perez-Gomez MV, et al. Phosphate, Microbiota and CKD. Nutrients 2021;13(4):1273. doi: 10.3390/nu13041273.
Chi M, Ma K, Wang J, Ding Z, Li Y, Zhu S, et al. The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease. J Immunol Res 2021;2021:5516035. doi: 10.1155/2021/5516035.
Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Fernandez-Fernandez B, et al. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. Toxins (Basel) 2018;10(7). doi: 10.3390/toxins10070300.
Cigarran Guldris S, Gonzalez Parra E, Cases Amenos A. Gut microbiota in chronic kidney disease. Nefrologia 2017;37(1):9–19. doi: 10.1016/j.nefro.2016.05.008.
Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2016;31(5):737–46. doi: 10.1093/ndt/gfv095.
Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009(114):S12–9. doi: 10.1038/ki.2009.402.
Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013;83(6):1010–6. doi: 10.1038/ki.2012.440.
Bertani B, Ruiz N. Function and Biogenesis of Lipopolysaccharides. EcoSal Plus 2018;8(1). doi: 10.1128/ecosalplus. ESP-0001-2018.
Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012;27(7):2686–93. doi: 10.1093/ndt/gfr624.
Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013;83(2):308–15. doi: 10.1038/ki.2012.345.
Khan MT, Nieuwdorp M, Backhed F. Microbial modulation of insulin sensitivity. Cell Metab 2014;20(5):753–60. doi: 10.1016/ j.cmet.2014.07.006.
Koppe L, Pelletier CC, Alix PM, Kalbacher E, Fouque D, Soulage CO, et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant 2014;29(9):1666–74. doi: 10.1093/ndt/gft435.
Evenepoel P, Stenvinkel P, Shanahan C, Pacifici R. Inflammation and gut dysbiosis as drivers of CKD-MBD. Nat Rev Nephrol 2023;19(10):646–57. doi: 10.1038/s41581-023-00736-7.
Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 2014;9(3):399–410. doi: 10.2217/fmb.13.165.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11(8):506–14. doi: 10.1038/nrgastro.2014.66.
Markowiak P, Slizewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017;9(9):1021. doi: 10.3390/nu9091021.
Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8(6):411–20. doi: 10.1038/nri2316.
Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr 2014;111(3):387–402. doi: 10.1017/S0007114513002560.
Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008;1(3):183–97. doi: 10.1038/mi.2008.5.
Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012;87(11):1046–53. doi: 10.1016/j.mayocp.2012.05.025.
Fayol-Messaoudi D, Berger CN, Coconnier-Polter MH, Lievin-Le Moal V, Servin AL. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 2005;71(10):6008–13. doi: 10.1128/AEM.71.10.6008-6013.2005.
Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 2007;104(18):7617–21. doi: 10.1073/pnas.0700440104.
Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011;7(11):639–46. doi: 10.1038/nrendo.2011.126.
Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014;25(4):657–70. doi: 10.1681/ASN.2013080905.
Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003;52(6):827–33. doi: 10.1136/gut.52.6.827.
Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009;296(5):G1140–9. doi: 10.1152/ajpgi.90534.2008.
Johnson-Henry KC, Hagen KE, Gordonpour M, Tompkins TA, Sherman PM. Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell Microbiol 2007;9(2):356–67. doi: 10.1111/j.1462-5822.2006.00791.x.
Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol 2000;78(1):80–8. doi: 10.1046/j.1440-1711.2000.00886.x.
Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000;84(3):197–215. doi: 10.1016/s0168-1656(00)00375-8.
Tian N, Li L, Ng JK, Li PK. The Potential Benefits and Controversies of Probiotics Use in Patients at Different Stages of Chronic Kidney Disease. Nutrients 2022;14(19). doi: 10.3390/nu14194044.
De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007;292(1):G358–68. doi: 10.1152/ajpgi.00052.2006.
Wagner S, Merkling T, Metzger M, Koppe L, Laville M, Boutron-Ruault MC, et al. Probiotic Intake and Inflammation in Patients With Chronic Kidney Disease: An Analysis of the CKD-REIN Cohort. Front Nutr 2022;9:772596. doi: 10.3389/fnut.2022.772596.
Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghiasvand R. The Impact of Probiotic Soy Milk Consumption on Oxidative Stress Among Type 2 Diabetic Kidney Disease Patients: A Randomized Controlled Clinical Trial. J Ren Nutr 2017;27(5):317–24. doi: 10.1053/j.jrn.2017.04.004.
Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clin J Am Soc Nephrol 2016;11(2):223–31. doi: 10.2215/CJN.05240515.
Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010;27(9):634–47. doi: 10.1007/s12325-010-0059-9.
Jia L, Jia Q, Yang J, Jia R, Zhang H. Efficacy of Probiotics Supplementation On Chronic Kidney Disease: a Systematic Review and Meta-Analysis. Kidney Blood Press Res 2018;43(5):1623–35. doi: 10.1159/000494677.
Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol 2017;18(1):35. doi: 10.1186/s12882-017-0457-1.
He S, Xiong Q, Tian C, Li L, Zhao J, Lin X, et al. Inulin-type prebiotics reduce serum uric acid levels via gut microbiota modulation: a randomized, controlled crossover trial in peritoneal dialysis patients. Eur J Nutr 2022;61(2):665–77. doi: 10.1007/s00394-021-02669-y.
Garcia-Martinez Y, Borriello M, Capolongo G, Ingrosso D, Perna AF. The Gut Microbiota in Kidney Transplantation: A Target for Personalized Therapy? Biology (Basel) 2023;12(2):163. doi: 10.3390/biology12020163.
Chan S, Hawley CM, Pascoe EM, Cao C, Campbell SB, Campbell KL, et al. Prebiotic Supplementation in Kidney Transplant Recipients for Preventing Infections and Gastrointestinal Upset: A Randomized Controlled Feasibility Study. J Ren Nutr 2022;32(6):718–25. doi: 10.1053/j.jrn.2022.02.006.
